These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29569727)

  • 1. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia.
    Derman R; Roman E; Smith-Nguyen GN; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2018 Jun; 93(6):E148-E150. PubMed ID: 29569727
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis].
    Ding SX; Zhao YH; Wang T; Guan J; Xing LM; Liu H; Wang GJ; Wang XM; Wu YH; Qu W; Song J; Wang HQ; Li LJ; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):178-183. PubMed ID: 38604795
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
    Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
    Auerbach M; Achebe MM; Thomsen LL; Derman RJ
    Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials.
    Wolf M; Auerbach M; Kalra PA; Glaspy J; Thomsen LL; Bhandari S
    Am J Hematol; 2021 Jan; 96(1):E11-E15. PubMed ID: 33027541
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
    Shi L; Zhao Y; Rao A
    Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
    Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
    Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Aksan A; Dignass A; Stein J
    Expert Rev Hematol; 2022 Apr; 15(4):383-384. PubMed ID: 33511892
    [No Abstract]   [Full Text] [Related]  

  • 19. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
    Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
    BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of outpatient treatment with intravenous iron in selected primary Care patients.
    Rivilla Marugán L; Lorente Aznar T; García-Erce JA
    Med Clin (Barc); 2020 Jan; 154(2):66-67. PubMed ID: 30497767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.